Previous studies in a rat model of Parkinson disease (PD) have shown that dyskinesia induced by L-DOPA—a treatment-limiting adverse effect of long-term administration—is caused by the release ...

The odds ratio for exposure to L-dopa in the IPD patients with PN was 12.4 (95% confidence interval, 1.4–109.1). There were no differences between the groups in the use of other PD drugs ...

By incorporating ingredients celebrated in traditional medicine, NeuroQuiet offers a holistic approach to auditory and ...

L-dopa, the front-line drug for treatment, acts by replacing the lost dopamine and has a duration of two to three hours.

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

The findings shed light on the molecular mechanism behind the drug levodopa (L-Dopa), widely used to treat Parkinson's disease. A hallmark of the condition is progressively diminishing dopamine ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

This distinction helps clarify how L-Dopa alleviates motor symptoms in Parkinson's disease but may not improve cognitive function. Movement initiation depends on slow dopamine signaling, contradicting ...

Six decades of the neurologist’s correspondence have been expertly woven into a collection of humanistic observations, ...

However, nicotine may modulate dopamine transmission and has clear motor effects when associated with L-DOPA, reducing L-DOPA-induced dyskinesias. Clinical trials have yielded inconclusive results ...